<?xml version='1.0' encoding='utf-8'?>
<document id="23625188"><sentence text="Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist."><entity charOffset="75-85" id="DDI-PubMed.23625188.s1.e0" text="mirabegron" /></sentence><sentence text="Mirabegron is a β3-adrenoceptor agonist for the treatment of overactive bladder"><entity charOffset="0-10" id="DDI-PubMed.23625188.s2.e0" text="Mirabegron" /></sentence><sentence text=" There has been little information published or presented about the involvement of cytochrome P450 (CYP) isoenzymes 3A and 2D6 in the metabolism of mirabegron in humans; in vitro data indicate that oxidative metabolism is primarily mediated by CYP3A with a minor role for CYP2D6"><entity charOffset="148-158" id="DDI-PubMed.23625188.s3.e0" text="mirabegron" /></sentence><sentence text="" /><sentence text="To determine to what extent CYP3A and CYP2D6 isoenzymes are involved in mirabegron metabolism"><entity charOffset="72-82" id="DDI-PubMed.23625188.s5.e0" text="mirabegron" /></sentence><sentence text="" /><sentence text="Two open-label, randomized, one-sequence crossover drug-drug interaction studies in healthy subjects were conducted to assess the effect of ketoconazole and rifampicin on the pharmacokinetics of mirabegron and two parallel-group studies in healthy subjects with either known confirmed or predicted CYP2D6 phenotype"><entity charOffset="140-152" id="DDI-PubMed.23625188.s7.e0" text="ketoconazole" /><entity charOffset="157-167" id="DDI-PubMed.23625188.s7.e1" text="rifampicin" /><entity charOffset="195-205" id="DDI-PubMed.23625188.s7.e2" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.23625188.s7.e0" e2="DDI-PubMed.23625188.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s7.e0" e2="DDI-PubMed.23625188.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s7.e0" e2="DDI-PubMed.23625188.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23625188.s7.e1" e2="DDI-PubMed.23625188.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s7.e1" e2="DDI-PubMed.23625188.s7.e2" /></sentence><sentence text="" /><sentence text="Co-administration of multiple dosages of 400 mg/day ketoconazole with a single 100 mg mirabegron oral controlled absorption system (OCAS) dose increased mirabegron maximum concentration (C(max)) and area under the curve extrapolated to infinity (AUC∞) to 145 % (90 % confidence interval [CI] 123-172 %] and 181 % (90 % CI 163-201 %), respectively"><entity charOffset="52-64" id="DDI-PubMed.23625188.s9.e0" text="ketoconazole" /><entity charOffset="86-96" id="DDI-PubMed.23625188.s9.e1" text="mirabegron" /><entity charOffset="153-163" id="DDI-PubMed.23625188.s9.e2" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.23625188.s9.e0" e2="DDI-PubMed.23625188.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s9.e0" e2="DDI-PubMed.23625188.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s9.e0" e2="DDI-PubMed.23625188.s9.e2" /><pair ddi="false" e1="DDI-PubMed.23625188.s9.e1" e2="DDI-PubMed.23625188.s9.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s9.e1" e2="DDI-PubMed.23625188.s9.e2" /></sentence><sentence text=" Co-administration of multiple dosages of 600 mg/day rifampicin with a single 100 mg mirabegron OCAS dose decreased mirabegron C max and AUC∞ to 65 % (90 % CI 50-86 %) and 56 % (90 % CI 49-65 %), respectively, without an effect on terminal elimination half-life (t(½))"><entity charOffset="53-63" id="DDI-PubMed.23625188.s10.e0" text="rifampicin" /><entity charOffset="116-128" id="DDI-PubMed.23625188.s10.e1" text="mirabegron C" /><pair ddi="false" e1="DDI-PubMed.23625188.s10.e0" e2="DDI-PubMed.23625188.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s10.e0" e2="DDI-PubMed.23625188.s10.e1" /></sentence><sentence text=" The urinary excretion of mirabegron was increased by ketoconazole and decreased by rifampicin, reflecting the AUC changes, whereas renal clearance was not affected"><entity charOffset="26-36" id="DDI-PubMed.23625188.s11.e0" text="mirabegron" /><entity charOffset="54-66" id="DDI-PubMed.23625188.s11.e1" text="ketoconazole" /><entity charOffset="84-94" id="DDI-PubMed.23625188.s11.e2" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.23625188.s11.e0" e2="DDI-PubMed.23625188.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s11.e0" e2="DDI-PubMed.23625188.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s11.e0" e2="DDI-PubMed.23625188.s11.e2" /><pair ddi="false" e1="DDI-PubMed.23625188.s11.e1" e2="DDI-PubMed.23625188.s11.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s11.e1" e2="DDI-PubMed.23625188.s11.e2" /></sentence><sentence text=" Ketoconazole decreased mirabegron t ½ from 50"><entity charOffset="1-13" id="DDI-PubMed.23625188.s12.e0" text="Ketoconazole" /><entity charOffset="24-34" id="DDI-PubMed.23625188.s12.e1" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.23625188.s12.e0" e2="DDI-PubMed.23625188.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s12.e0" e2="DDI-PubMed.23625188.s12.e1" /></sentence><sentence text="9 to 37" /><sentence text="6 h suggesting that volume of distribution as well as first-pass effect decreased" /><sentence text=" Rifampicin did not affect mirabegron t ½, suggesting that it affects first pass through the intestinal wall or liver"><entity charOffset="1-11" id="DDI-PubMed.23625188.s15.e0" text="Rifampicin" /><entity charOffset="27-37" id="DDI-PubMed.23625188.s15.e1" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.23625188.s15.e0" e2="DDI-PubMed.23625188.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s15.e0" e2="DDI-PubMed.23625188.s15.e1" /></sentence><sentence text=" Rifampicin greatly increased the ratio to parent drug of the presumed CYP-mediated mirabegron metabolites M8 and M15 by 777 and 646 %"><entity charOffset="1-11" id="DDI-PubMed.23625188.s16.e0" text="Rifampicin" /><entity charOffset="84-94" id="DDI-PubMed.23625188.s16.e1" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.23625188.s16.e0" e2="DDI-PubMed.23625188.s16.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s16.e0" e2="DDI-PubMed.23625188.s16.e1" /></sentence><sentence text=" Steady-state mirabegron pharmacokinetic parameters (50 and 100 mg mirabegron OCAS) were similar in 13 CYP2D6 poor, 40 intermediate, and 99 extensive metabolizers, whereas C max and AUC under the dosing interval τ of 24 h (AUCτ) were 30-47 % lower in 10 ultrarapid metabolizers"><entity charOffset="14-24" id="DDI-PubMed.23625188.s17.e0" text="mirabegron" /></sentence><sentence text=" After administration of 160 mg mirabegron immediate release, C(max) was 14 % and AUC∞ 19 % higher in eight poor metabolizers than in eight extensive metabolizers (phenotyped) with similar t ½"><entity charOffset="32-42" id="DDI-PubMed.23625188.s18.e0" text="mirabegron" /></sentence><sentence text=" All treatments were well tolerated" /><sentence text="" /><sentence text="Mirabegron is metabolized by CYP3A and to a minor extent by CYP2D6 in humans"><entity charOffset="0-10" id="DDI-PubMed.23625188.s21.e0" text="Mirabegron" /></sentence><sentence text=" Mirabegron is not considered a sensitive substrate of CYP3A in vivo, as ketoconazole increased mirabegron exposure by less than 2-fold"><entity charOffset="1-11" id="DDI-PubMed.23625188.s22.e0" text="Mirabegron" /><entity charOffset="73-85" id="DDI-PubMed.23625188.s22.e1" text="ketoconazole" /><entity charOffset="96-106" id="DDI-PubMed.23625188.s22.e2" text="mirabegron" /><pair ddi="false" e1="DDI-PubMed.23625188.s22.e0" e2="DDI-PubMed.23625188.s22.e0" /><pair ddi="false" e1="DDI-PubMed.23625188.s22.e0" e2="DDI-PubMed.23625188.s22.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s22.e0" e2="DDI-PubMed.23625188.s22.e2" /><pair ddi="false" e1="DDI-PubMed.23625188.s22.e1" e2="DDI-PubMed.23625188.s22.e1" /><pair ddi="false" e1="DDI-PubMed.23625188.s22.e1" e2="DDI-PubMed.23625188.s22.e2" /></sentence><sentence text=" The effect of CYP2D6 phenotype on mirabegron exposure is small and likely of limited clinical importance"><entity charOffset="35-45" id="DDI-PubMed.23625188.s23.e0" text="mirabegron" /></sentence><sentence text="" /></document>